ArticleFrontiers in oncology2024
Non-melanoma skin cancer treated with hypofractionated 192-Ir contact brachitherapy: a single institution series.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HDR Brachytherapy in the Treatment of Skin Kaposi Sarcoma: A Mono-Institutional Series.Cancers · 2026Article
- Radiotherapeutic Modalities and Advancements in the Treatment of Cutaneous Malignancies.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-melanoma skin carcinoma (NMSC) is the most common malignant tumor in the population, with a steadily increasing incidence due to an aging population and sun exposure. The two main subtypes of NMSC are basal cell carcinoma(BCC) and squamous cell carcinoma(SCC). Therapeutic management of NMSC includes a variety of options, such as surgery, radiotherapy, and topical or systemic treatments. High-dose fractionated contact brachytherapy (c-HDR-BRT) is a viable therapeutic option for treating NMSCs. Methods: At our center, we treated 39 patients with BCC or SCC, with a total of 46 lesions, treated with c-HDR-BRT. The patients underwent two different radiotherapy schedules: 40 Gy in four fractions and 30 Gy in three fractions. Results: Two-year results showed 100% local control (LC) and 100% disease-specific survival (DSS), indicating high efficacy of c-HDR-BRT in terms of tumor control. Furthermore, the observed toxicity profile was favorable with no significant late toxicity. Conclusions: These results suggest that c-HDR-BRT represents a viable therapeutic alternative for NMSC, combining high oncological efficacy with an acceptable safety profile, while minimizing the aesthetic and functional impact of therapy. Finally, the study emphasizes the importance of personalization of treatment and careful evaluation of individual cases to optimize the treatment approach in NMSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.